Global Cancer Diagnostics

Cancer Diagnostics Comprehensive Study by Type (Platform-based, Instrument-based), Application (Hospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institute, Other), Method (Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging), Cancer (Leukemia, Colon and Rectal, Liver, Melanoma, Endometrial, Other) Players and Region - Global Market Outlook to 2028

Cancer Diagnostics Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Cancer Diagnostics Market?

Cancer is a disease that causes uncontrolled growth and division of cells. Some types of cancer cause rapid cell growth of the cells while others cause cells to grow and divide at a slower rate. There are many causes of cancer such as heavy alcohol consumption, excess body weight, physical inactivity, poor nutrition etc. A cancer diagnosis is done by physical exam, laboratory studies, imaging studies and biopsy. To confirm the diagnosis of most cancers, a biopsy is done in which a tissue sample is removed from the suspected tumor and studied under a microscope to check for cancer cells.

Highlights from Cancer Diagnostics Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledGE Healthcare (United States), Abbott (United States), GlaxoSmithKline Plc. (United Kingdom), Roche Holding AG (Switzerland), Siemens Healthcare GmbH (Germany), Ambry Genetics (United States), AstraZeneca (United Kingdom), Genoptix Inc. (United States), Illumina, Inc. (United States) and Philips Healthcare (Netherlands)


Cancer Diagnostics market companies operating in these industries are focusing more on efficient growth, improvement of operational efficiency and productivity, achieving high safety standards, and focusing on maintaining sustainable development. The market is highly competitive with a few players occupying the major share. The key players are highly focused on developing and innovating new strategies to maintain their market position and customer base. The companies are coming up with partnerships or agreements along with planning strategic activities such as partnerships, product launches, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Cancer Diagnostics market throughout the forecasted period.

GE Healthcare (United States), Abbott (United States), GlaxoSmithKline Plc. (United Kingdom), Roche Holding AG (Switzerland), Siemens Healthcare GmbH (Germany), Ambry Genetics (United States), AstraZeneca (United Kingdom), Genoptix Inc. (United States), Illumina, Inc. (United States) and Philips Healthcare (Netherlands) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Hologic, Inc. (United States), Eli Lilly and Company (United States), Becton Dickinson & Company (United States) and Pfizer (United States).

Cancer Diagnostics Market Segmentation:
ScopeSub-Segments
Application / End UserHospitals, Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institute and Other
TypePlatform-based and Instrument-based
MethodBiopsy,Endoscopy,Tumor Biomarker Tests,Imaging
CancerLeukemia,Colon and Rectal,Liver,Melanoma,Endometrial,Other


On the basis of geography, the market of Cancer Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancements in Diagnostics

Market Growth Drivers:
Increasing Number of Cancer Patients Worldwide, Increasing Awareness about Cancer among People and Government Initiatives about Prevention of the Disease

Challenges:
High Cost Entailed In Performing Diagnosis

Restraints:
Stringent Regulatory Framework and Prolonged Time of Approvals for Product Launching

Opportunities:
Increased Cancer-Related Deaths Worldwide and Growing Health Care Infrastructure in Developing Countries

Key Target Audience
Cancer Diagnostics Instrument Manufacturers, Research Institutes, Research Professionals, Government Body & Associations and End-user

Market Leaders & Development Strategies
In July 2022, GSK completes the acquisition of Sierra Oncology . a California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, the acquisition of Sierra Oncology includes momelotinib, a late-stage potential new medicine with a unique dual mechanism of action that may address the critical unmet medical needs of myelofibrosis patients with anaemia.
On 31st May 2019, Roche and GE healthcare launched NAVIFY Tumor Board 2.0, the first collaboration product. Incorporating medical image viewing and storage capabilities with other patient data, the product enables tumor boards, multi-disciplinary teams who determine treatment plans for cancer patients to have a more comprehensive view of each patient in one place.


Report Objectives / Segmentation Covered

By Type
  • Platform-based
  • Instrument-based
By Application
  • Hospitals
  • Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Cancer Research Institute
  • Other
By Method
  • Biopsy
  • Endoscopy
  • Tumor Biomarker Tests
  • Imaging

By Cancer
  • Leukemia
  • Colon and Rectal
  • Liver
  • Melanoma
  • Endometrial
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Cancer Patients Worldwide
      • 3.2.2. Increasing Awareness about Cancer among People
      • 3.2.3. Government Initiatives about Prevention of the Disease
    • 3.3. Market Challenges
      • 3.3.1. High Cost Entailed In Performing Diagnosis
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in Diagnostics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cancer Diagnostics, by Type, Application, Method, Cancer and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cancer Diagnostics (Value)
      • 5.2.1. Global Cancer Diagnostics by: Type (Value)
        • 5.2.1.1. Platform-based
        • 5.2.1.2. Instrument-based
      • 5.2.2. Global Cancer Diagnostics by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Diagnostic Laboratories
        • 5.2.2.3. Diagnostic Imaging Centers
        • 5.2.2.4. Cancer Research Institute
        • 5.2.2.5. Other
      • 5.2.3. Global Cancer Diagnostics by: Method (Value)
        • 5.2.3.1. Biopsy
        • 5.2.3.2. Endoscopy
        • 5.2.3.3. Tumor Biomarker Tests
        • 5.2.3.4. Imaging
      • 5.2.4. Global Cancer Diagnostics by: Cancer (Value)
        • 5.2.4.1. Leukemia
        • 5.2.4.2. Colon and Rectal
        • 5.2.4.3. Liver
        • 5.2.4.4. Melanoma
        • 5.2.4.5. Endometrial
        • 5.2.4.6. Other
      • 5.2.5. Global Cancer Diagnostics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Cancer Diagnostics (Price)
      • 5.3.1. Global Cancer Diagnostics by: Type (Price)
  • 6. Cancer Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GE Healthcare (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Roche Holding AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Siemens Healthcare GmbH (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Ambry Genetics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AstraZeneca (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Genoptix Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Illumina, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Philips Healthcare (Netherlands)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cancer Diagnostics Sale, by Type, Application, Method, Cancer and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cancer Diagnostics (Value)
      • 7.2.1. Global Cancer Diagnostics by: Type (Value)
        • 7.2.1.1. Platform-based
        • 7.2.1.2. Instrument-based
      • 7.2.2. Global Cancer Diagnostics by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Diagnostic Laboratories
        • 7.2.2.3. Diagnostic Imaging Centers
        • 7.2.2.4. Cancer Research Institute
        • 7.2.2.5. Other
      • 7.2.3. Global Cancer Diagnostics by: Method (Value)
        • 7.2.3.1. Biopsy
        • 7.2.3.2. Endoscopy
        • 7.2.3.3. Tumor Biomarker Tests
        • 7.2.3.4. Imaging
      • 7.2.4. Global Cancer Diagnostics by: Cancer (Value)
        • 7.2.4.1. Leukemia
        • 7.2.4.2. Colon and Rectal
        • 7.2.4.3. Liver
        • 7.2.4.4. Melanoma
        • 7.2.4.5. Endometrial
        • 7.2.4.6. Other
      • 7.2.5. Global Cancer Diagnostics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Cancer Diagnostics (Price)
      • 7.3.1. Global Cancer Diagnostics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cancer Diagnostics: by Type(USD Million)
  • Table 2. Cancer Diagnostics Platform-based , by Region USD Million (2017-2022)
  • Table 3. Cancer Diagnostics Instrument-based , by Region USD Million (2017-2022)
  • Table 4. Cancer Diagnostics: by Application(USD Million)
  • Table 5. Cancer Diagnostics Hospitals , by Region USD Million (2017-2022)
  • Table 6. Cancer Diagnostics Diagnostic Laboratories , by Region USD Million (2017-2022)
  • Table 7. Cancer Diagnostics Diagnostic Imaging Centers , by Region USD Million (2017-2022)
  • Table 8. Cancer Diagnostics Cancer Research Institute , by Region USD Million (2017-2022)
  • Table 9. Cancer Diagnostics Other , by Region USD Million (2017-2022)
  • Table 10. Cancer Diagnostics: by Method(USD Million)
  • Table 11. Cancer Diagnostics Biopsy , by Region USD Million (2017-2022)
  • Table 12. Cancer Diagnostics Endoscopy , by Region USD Million (2017-2022)
  • Table 13. Cancer Diagnostics Tumor Biomarker Tests , by Region USD Million (2017-2022)
  • Table 14. Cancer Diagnostics Imaging , by Region USD Million (2017-2022)
  • Table 15. Cancer Diagnostics: by Cancer(USD Million)
  • Table 16. Cancer Diagnostics Leukemia , by Region USD Million (2017-2022)
  • Table 17. Cancer Diagnostics Colon and Rectal , by Region USD Million (2017-2022)
  • Table 18. Cancer Diagnostics Liver , by Region USD Million (2017-2022)
  • Table 19. Cancer Diagnostics Melanoma , by Region USD Million (2017-2022)
  • Table 20. Cancer Diagnostics Endometrial , by Region USD Million (2017-2022)
  • Table 21. Cancer Diagnostics Other , by Region USD Million (2017-2022)
  • Table 22. South America Cancer Diagnostics, by Country USD Million (2017-2022)
  • Table 23. South America Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 24. South America Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 25. South America Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 26. South America Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 27. Brazil Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 28. Brazil Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 29. Brazil Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 30. Brazil Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 31. Argentina Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 32. Argentina Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 33. Argentina Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 34. Argentina Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 35. Rest of South America Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 36. Rest of South America Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 37. Rest of South America Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 38. Rest of South America Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 39. Asia Pacific Cancer Diagnostics, by Country USD Million (2017-2022)
  • Table 40. Asia Pacific Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 41. Asia Pacific Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 42. Asia Pacific Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 43. Asia Pacific Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 44. China Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 45. China Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 46. China Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 47. China Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 48. Japan Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 49. Japan Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 50. Japan Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 51. Japan Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 52. India Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 53. India Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 54. India Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 55. India Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 56. South Korea Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 57. South Korea Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 58. South Korea Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 59. South Korea Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 60. Taiwan Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 61. Taiwan Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 62. Taiwan Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 63. Taiwan Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 64. Australia Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 65. Australia Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 66. Australia Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 67. Australia Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 70. Rest of Asia-Pacific Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 71. Rest of Asia-Pacific Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 72. Europe Cancer Diagnostics, by Country USD Million (2017-2022)
  • Table 73. Europe Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 74. Europe Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 75. Europe Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 76. Europe Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 77. Germany Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 78. Germany Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 79. Germany Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 80. Germany Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 81. France Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 82. France Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 83. France Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 84. France Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 85. Italy Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 86. Italy Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 87. Italy Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 88. Italy Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 89. United Kingdom Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 90. United Kingdom Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 91. United Kingdom Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 92. United Kingdom Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 93. Netherlands Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 94. Netherlands Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 95. Netherlands Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 96. Netherlands Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 97. Rest of Europe Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 98. Rest of Europe Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 99. Rest of Europe Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 100. Rest of Europe Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 101. MEA Cancer Diagnostics, by Country USD Million (2017-2022)
  • Table 102. MEA Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 103. MEA Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 104. MEA Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 105. MEA Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 106. Middle East Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 107. Middle East Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 108. Middle East Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 109. Middle East Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 110. Africa Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 111. Africa Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 112. Africa Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 113. Africa Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 114. North America Cancer Diagnostics, by Country USD Million (2017-2022)
  • Table 115. North America Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 116. North America Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 117. North America Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 118. North America Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 119. United States Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 120. United States Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 121. United States Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 122. United States Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 123. Canada Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 124. Canada Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 125. Canada Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 126. Canada Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 127. Mexico Cancer Diagnostics, by Type USD Million (2017-2022)
  • Table 128. Mexico Cancer Diagnostics, by Application USD Million (2017-2022)
  • Table 129. Mexico Cancer Diagnostics, by Method USD Million (2017-2022)
  • Table 130. Mexico Cancer Diagnostics, by Cancer USD Million (2017-2022)
  • Table 131. Cancer Diagnostics: by Type(USD/Units)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Cancer Diagnostics: by Type(USD Million)
  • Table 143. Cancer Diagnostics Platform-based , by Region USD Million (2023-2028)
  • Table 144. Cancer Diagnostics Instrument-based , by Region USD Million (2023-2028)
  • Table 145. Cancer Diagnostics: by Application(USD Million)
  • Table 146. Cancer Diagnostics Hospitals , by Region USD Million (2023-2028)
  • Table 147. Cancer Diagnostics Diagnostic Laboratories , by Region USD Million (2023-2028)
  • Table 148. Cancer Diagnostics Diagnostic Imaging Centers , by Region USD Million (2023-2028)
  • Table 149. Cancer Diagnostics Cancer Research Institute , by Region USD Million (2023-2028)
  • Table 150. Cancer Diagnostics Other , by Region USD Million (2023-2028)
  • Table 151. Cancer Diagnostics: by Method(USD Million)
  • Table 152. Cancer Diagnostics Biopsy , by Region USD Million (2023-2028)
  • Table 153. Cancer Diagnostics Endoscopy , by Region USD Million (2023-2028)
  • Table 154. Cancer Diagnostics Tumor Biomarker Tests , by Region USD Million (2023-2028)
  • Table 155. Cancer Diagnostics Imaging , by Region USD Million (2023-2028)
  • Table 156. Cancer Diagnostics: by Cancer(USD Million)
  • Table 157. Cancer Diagnostics Leukemia , by Region USD Million (2023-2028)
  • Table 158. Cancer Diagnostics Colon and Rectal , by Region USD Million (2023-2028)
  • Table 159. Cancer Diagnostics Liver , by Region USD Million (2023-2028)
  • Table 160. Cancer Diagnostics Melanoma , by Region USD Million (2023-2028)
  • Table 161. Cancer Diagnostics Endometrial , by Region USD Million (2023-2028)
  • Table 162. Cancer Diagnostics Other , by Region USD Million (2023-2028)
  • Table 163. South America Cancer Diagnostics, by Country USD Million (2023-2028)
  • Table 164. South America Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 165. South America Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 166. South America Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 167. South America Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 168. Brazil Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 169. Brazil Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 170. Brazil Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 171. Brazil Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 172. Argentina Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 173. Argentina Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 174. Argentina Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 175. Argentina Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 176. Rest of South America Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 177. Rest of South America Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 178. Rest of South America Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 179. Rest of South America Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 180. Asia Pacific Cancer Diagnostics, by Country USD Million (2023-2028)
  • Table 181. Asia Pacific Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 182. Asia Pacific Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 183. Asia Pacific Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 184. Asia Pacific Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 185. China Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 186. China Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 187. China Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 188. China Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 189. Japan Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 190. Japan Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 191. Japan Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 192. Japan Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 193. India Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 194. India Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 195. India Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 196. India Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 197. South Korea Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 198. South Korea Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 199. South Korea Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 200. South Korea Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 201. Taiwan Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 202. Taiwan Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 203. Taiwan Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 204. Taiwan Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 205. Australia Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 206. Australia Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 207. Australia Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 208. Australia Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 209. Rest of Asia-Pacific Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 210. Rest of Asia-Pacific Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 211. Rest of Asia-Pacific Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 212. Rest of Asia-Pacific Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 213. Europe Cancer Diagnostics, by Country USD Million (2023-2028)
  • Table 214. Europe Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 215. Europe Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 216. Europe Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 217. Europe Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 218. Germany Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 219. Germany Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 220. Germany Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 221. Germany Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 222. France Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 223. France Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 224. France Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 225. France Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 226. Italy Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 227. Italy Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 228. Italy Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 229. Italy Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 230. United Kingdom Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 231. United Kingdom Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 232. United Kingdom Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 233. United Kingdom Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 234. Netherlands Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 235. Netherlands Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 236. Netherlands Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 237. Netherlands Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 238. Rest of Europe Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 239. Rest of Europe Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 240. Rest of Europe Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 241. Rest of Europe Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 242. MEA Cancer Diagnostics, by Country USD Million (2023-2028)
  • Table 243. MEA Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 244. MEA Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 245. MEA Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 246. MEA Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 247. Middle East Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 248. Middle East Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 249. Middle East Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 250. Middle East Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 251. Africa Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 252. Africa Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 253. Africa Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 254. Africa Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 255. North America Cancer Diagnostics, by Country USD Million (2023-2028)
  • Table 256. North America Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 257. North America Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 258. North America Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 259. North America Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 260. United States Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 261. United States Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 262. United States Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 263. United States Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 264. Canada Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 265. Canada Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 266. Canada Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 267. Canada Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 268. Mexico Cancer Diagnostics, by Type USD Million (2023-2028)
  • Table 269. Mexico Cancer Diagnostics, by Application USD Million (2023-2028)
  • Table 270. Mexico Cancer Diagnostics, by Method USD Million (2023-2028)
  • Table 271. Mexico Cancer Diagnostics, by Cancer USD Million (2023-2028)
  • Table 272. Cancer Diagnostics: by Type(USD/Units)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cancer Diagnostics: by Type USD Million (2017-2022)
  • Figure 5. Global Cancer Diagnostics: by Application USD Million (2017-2022)
  • Figure 6. Global Cancer Diagnostics: by Method USD Million (2017-2022)
  • Figure 7. Global Cancer Diagnostics: by Cancer USD Million (2017-2022)
  • Figure 8. South America Cancer Diagnostics Share (%), by Country
  • Figure 9. Asia Pacific Cancer Diagnostics Share (%), by Country
  • Figure 10. Europe Cancer Diagnostics Share (%), by Country
  • Figure 11. MEA Cancer Diagnostics Share (%), by Country
  • Figure 12. North America Cancer Diagnostics Share (%), by Country
  • Figure 13. Global Cancer Diagnostics: by Type USD/Units (2017-2022)
  • Figure 14. Global Cancer Diagnostics share by Players 2022 (%)
  • Figure 15. Global Cancer Diagnostics share by Players (Top 3) 2022(%)
  • Figure 16. Global Cancer Diagnostics share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 19. GE Healthcare (United States) Revenue: by Geography 2022
  • Figure 20. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 21. Abbott (United States) Revenue: by Geography 2022
  • Figure 22. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 24. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Roche Holding AG (Switzerland) Revenue: by Geography 2022
  • Figure 26. Siemens Healthcare GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Siemens Healthcare GmbH (Germany) Revenue: by Geography 2022
  • Figure 28. Ambry Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 29. Ambry Genetics (United States) Revenue: by Geography 2022
  • Figure 30. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. AstraZeneca (United Kingdom) Revenue: by Geography 2022
  • Figure 32. Genoptix Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Genoptix Inc. (United States) Revenue: by Geography 2022
  • Figure 34. Illumina, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Illumina, Inc. (United States) Revenue: by Geography 2022
  • Figure 36. Philips Healthcare (Netherlands) Revenue, Net Income and Gross profit
  • Figure 37. Philips Healthcare (Netherlands) Revenue: by Geography 2022
  • Figure 38. Global Cancer Diagnostics: by Type USD Million (2023-2028)
  • Figure 39. Global Cancer Diagnostics: by Application USD Million (2023-2028)
  • Figure 40. Global Cancer Diagnostics: by Method USD Million (2023-2028)
  • Figure 41. Global Cancer Diagnostics: by Cancer USD Million (2023-2028)
  • Figure 42. South America Cancer Diagnostics Share (%), by Country
  • Figure 43. Asia Pacific Cancer Diagnostics Share (%), by Country
  • Figure 44. Europe Cancer Diagnostics Share (%), by Country
  • Figure 45. MEA Cancer Diagnostics Share (%), by Country
  • Figure 46. North America Cancer Diagnostics Share (%), by Country
  • Figure 47. Global Cancer Diagnostics: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • GE Healthcare (United States)
  • Abbott (United States)
  • GlaxoSmithKline Plc. (United Kingdom)
  • Roche Holding AG (Switzerland)
  • Siemens Healthcare GmbH (Germany)
  • Ambry Genetics (United States)
  • AstraZeneca (United Kingdom)
  • Genoptix Inc. (United States)
  • Illumina, Inc. (United States)
  • Philips Healthcare (Netherlands)
Additional players considered in the study are as follows:
Hologic, Inc. (United States) , Eli Lilly and Company (United States) , Becton Dickinson & Company (United States) , Pfizer (United States)
Select User Access Type

Key Highlights of Report


May 2023 231 Pages 79 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cancer Diagnostics Quantitative research analysis
Global Cancer Diagnostics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing Number of Cancer Patients Worldwide " is seen as one of major growth factors of Cancer Diagnostics Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Cancer Diagnostics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Cancer Diagnostics Report?

Have a Query? Click Here

Other Related Reports

Respiratory Diagnostics Comprehensive Study by Type (Mechanical Tests, OSA Diagnostic Tests, Imaging Tests, Others), Application (Hospital/Clinical Laboratories, Reference Laboratories, Physician Off...
$ 3750
Vocal Biomarkers Comprehensive Study by Type (Amplitude, Error rate, Frequency, Vocal rise or fall time, Voice tremor, Pitch, Others), Indication (Psychiatric Disorders, Neurological Disorders, Respi...
$ 3750
High-Throughput Screening Comprehensive Study by Type (Reagents & Assay Kits, Instruments, Consumables & Accessories, Software, Services), Application (Chemical Biology Programs, Cell- & Organ-Based ...
$ 3750
Hemorrhagic Shock Treatment Comprehensive Study by Causes (Severe Burns, Deep Cuts, Gunshot Wounds, Others), Diagnosis (X-rays, Blood tests, Ultrasound, CT scan, MRI), Symptoms (Abdominal Pain, Abdom...
$ 3500
NewBorn Screening Comprehensive Study by Type (Instruments {Newborn Disorder Screening Instruments, Newborn Hearing Screening Instruments (Hearing Screening Devices and Hearing Screening Accessories)...
$ 3750
Interventional Radiology Comprehensive Study by Type (X-ray, Computed Tomography, Magnetic Resonance Imaging (MRI), Ultrasound), Application (Oncology, Cardiology, Urology & Nephrology, Gastroenterol...
$ 3750